Amlodipine Cost in Hawaii 2026: Cash Price, Medicaid, Insurance, and Compounding

What Does Amlodipine Actually Cost in Hawaii in 2026?

Generic amlodipine at Hawaiian retail pharmacies averages about $8 per month in 2026 on a cash-pay basis. That figure applies to the standard 30-tablet supply of 5 mg or 10 mg tablets at chains such as Longs Drugs (CVS), Walmart, and Costco, as well as independent island pharmacies. The branded Norvasc still carries a list price near $80 per month, but virtually no clinician prescribes the brand when the generic is therapeutically identical.

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA in 1992 for hypertension and angina [1]. Its pharmacokinetic profile, including a 30-to-50-hour half-life and once-daily dosing, makes adherence straightforward and contributed to its strong outcome data in large randomized trials [2]. The ASCOT-BPLA trial (N=19,257) published in The Lancet in 2005 showed that an amlodipine-based regimen reduced fatal and non-fatal stroke by 23% (P<0.0003) and all-cause mortality by 11% (P=0.0247) compared with an atenolol-based regimen over a median 5.5-year follow-up [3]. That evidence base is part of why amlodipine appears on virtually every major hypertension formulary worldwide.

Despite strong clinical evidence, Hawaii's geography creates pharmacy-access barriers. Patients on neighbor islands (Maui, Kauai, Molokai, Lanai, Hawaii Island) sometimes face a narrower choice of pharmacies than Oahu residents. Shipping times from mainland mail-order pharmacies can stretch to five or more days, which makes identifying a local low-cost option especially relevant.

Price comparison by channel in Hawaii (2026 estimates):

| Supply channel | Estimated monthly cost | |---|---| | Retail pharmacy, cash pay (generic) | ~$8 | | Retail pharmacy, GoodRx or similar coupon | $4, $10 | | Mail-order (90-day supply, divided) | $5, $9/month equivalent | | Branded Norvasc, no insurance | ~$80 | | 503A compounding pharmacy | $0 (qualifying patients) |

The Eighth Report of the Joint National Committee (JNC 8) recommends thiazide diuretics, ACE inhibitors, ARBs, or calcium channel blockers as first-line agents for most adults with hypertension [4]. Amlodipine, as a CCB, fits that first-line slot, which reinforces why insurers and Medicaid programs generally prefer to list it, even though Hawaii Med-QUEST currently does not classify it as a preferred covered drug for most adult members.

Does Hawaii Medicaid (Med-QUEST) Cover Amlodipine?

Hawaii Med-QUEST does not currently list amlodipine as a preferred covered drug for most adult beneficiaries. This is a notable gap given the drug's strong evidence base and low generic cost. Med-QUEST members who need amlodipine should request a prior authorization (PA) from their managed care plan. Each of Hawaii's Med-QUEST managed care organizations (AlohaCare, Ohana Health Plan, UnitedHealthcare Community Plan, and Kaiser Permanente Hawaii) maintains its own preferred drug list (PDL), and coverage determinations may differ between plans.

The American Heart Association's 2023 Hypertension Guidelines, co-authored with the American College of Cardiology, specifically identify calcium channel blockers as first-line pharmacotherapy for hypertension in adults [5]. A prescriber can use that guideline language to support a PA request if Med-QUEST or a managed care plan denies initial coverage.

Patients who do not qualify for a PA waiver still benefit from the low cash price. At $8 per month, generic amlodipine is already cheaper than many Medicaid copays for other drug classes. The Hawaii Health Connector (the state's ACA marketplace) plan formularies vary by carrier, so members should verify their specific plan's preferred drug list before filling.

If a PA is denied, the prescriber may substitute amlodipine with another CCB that the plan prefers, or submit an appeal citing the ASCOT-BPLA outcome data [3] and JNC 8 first-line status [4]. Hawaii law requires managed care plans to respond to expedited PA requests within 72 hours for urgent clinical situations.

Is Compounded Amlodipine Legal in Hawaii?

Yes. Hawaii permits 503A compounding pharmacies to prepare amlodipine for individual patients with a valid, patient-specific prescription. Federal law under 21 U.S.C. Section 503A governs traditional compounding pharmacies and requires a licensed prescriber's order, a patient-practitioner relationship, and that the compound not be commercially available in the exact form prescribed [6].

Compounded amlodipine is most commonly prepared as an oral suspension or a transdermal gel, particularly for pediatric patients who cannot swallow tablets, or for adults requiring non-standard doses. The FDA's guidance on compounding distinguishes 503A (patient-specific) pharmacies from 503B outsourcing facilities; only 503A pharmacies may dispense directly to a named patient in Hawaii without bulk-sale restrictions [6].

Cost for compounded amlodipine from a 503A pharmacy in Hawaii can effectively reach $0 for patients whose prescriber works with a compounding pharmacy that participates in charitable programs or certain manufacturer patient-assistance arrangements. Patients should ask their prescriber explicitly whether a compounding pharmacy is appropriate for their situation; it is not appropriate simply to avoid cost if a commercial generic tablet is available and the patient can swallow it, since FDA-approved generics have demonstrated bioequivalence while compounded preparations do not carry that assurance [6].

Hawaii's Board of Pharmacy regulates 503A facilities under Hawaii Revised Statutes Chapter 328. A prescriber or patient can verify a pharmacy's current license status through the Hawaii Professional and Vocational Licensing Division online portal.

Amlodipine Insurance Coverage in Hawaii: What to Expect

Most private insurance plans available in Hawaii, including HMSA (the state's dominant Blue Cross Blue Shield affiliate) and Kaiser Permanente Hawaii, place generic amlodipine on Tier 1 of their formularies. Tier 1 copays in Hawaii typically range from $0 to $10 per 30-day fill, making insured patients largely unaffected by list-price fluctuations.

The 2023 AHA/ACC Hypertension Guidelines identify calcium channel blockers as Class I, Level A recommended therapy for hypertension, meaning the evidence is strong enough that most insurers have little clinical justification for a higher-tier placement [5]. Patients whose plans place amlodipine on Tier 2 or higher can request a formulary exception using this guideline citation.

Employer-sponsored plans administered under ERISA are governed by federal law rather than Hawaii insurance regulations, so formulary rules may differ from state-regulated plans. Federal employees in Hawaii covered by FEHB plans generally find amlodipine on Tier 1 as well. Medicare Part D plans covering Hawaii residents show variability: the CMS 2024 formulary data indicate that more than 90% of Part D stand-alone plans nationally cover generic amlodipine, most at $0, $5 after the low-income subsidy [7].

Tricare (for active-duty military and veterans in Hawaii, including those stationed at Joint Base Pearl Harbor-Hickam) covers generic amlodipine with a $0 copay at military treatment facility pharmacies and a nominal copay at civilian network pharmacies.

How Pfizer Savings Programs and Generic Discount Cards Work in Hawaii

Pfizer's branded Norvasc savings card historically reduced out-of-pocket cost for commercially insured patients to as low as $4 per month for Norvasc, but with generic amlodipine already available at $8 cash, the card offers marginal practical advantage for most Hawaii patients.

Third-party discount programs such as GoodRx, RxSaver, and NeedyMeds aggregate negotiated prices across Hawaii pharmacies. GoodRx prices for generic amlodipine at Oahu-area Walmart locations have been reported below $6 per month, and at Costco below $5. These coupons cannot be combined with insurance but are freely available to any cash-paying patient regardless of income or residency status.

Manufacturer patient-assistance programs (PAPs) from Pfizer (for Norvasc) require income documentation and typically serve uninsured patients earning below 400% of the federal poverty level. Hawaii-based patients can apply online or through their prescriber's office. Processing takes two to four weeks. Given the generic's low cost, PAPs are most relevant for patients who specifically need branded Norvasc for a documented clinical reason, which is uncommon.

The Health Resources and Services Administration (HRSA) 340B program allows qualifying Hawaii health centers, Federally Qualified Health Centers (FQHCs), and certain hospital outpatient departments to purchase drugs at steep discounts and pass savings to eligible patients [8]. Several FQHCs on Oahu and Hawaii Island participate in 340B; patients who receive care at those sites may access amlodipine at no cost or reduced cost regardless of their insurance status.

Telehealth Prescribing of Amlodipine in Hawaii

Telehealth prescribing of amlodipine is fully legal in Hawaii. Amlodipine is not a controlled substance, so none of the DEA's telemedicine-specific restrictions apply [9]. Hawaii law requires an established patient-provider relationship for prescribing, which telehealth platforms satisfy through an initial synchronous video visit or a documented asynchronous evaluation meeting state standards.

Hawaii's telehealth parity law (Act 226, 2016, codified at Hawaii Revised Statutes Section 431:10A-116.3) requires commercial insurers to reimburse covered telehealth services at the same rate as in-person services. This means a telehealth visit to obtain or renew an amlodipine prescription carries the same insurance billing as an office visit. Med-QUEST managed care plans similarly reimburse telehealth encounters under state guidance issued during and after the COVID-19 public health emergency.

A telehealth prescriber evaluating a Hawaii patient for amlodipine should confirm blood pressure readings taken at home (or at a local pharmacy kiosk), review prior medication history, assess for contraindications (severe aortic stenosis, known hypersensitivity), and document baseline renal and hepatic function if clinically indicated [1]. JNC 8 recommends a goal blood pressure of <140/90 mmHg for most adults and <150/90 mmHg for adults 60 years or older without diabetes or chronic kidney disease [4].

The table below outlines a practical decision framework for Hawaii telehealth patients seeking amlodipine:

| Patient situation | Recommended first step | |---|---| | Uninsured, cash-pay | Request generic + GoodRx coupon at nearest pharmacy | | Med-QUEST member, amlodipine not on PDL | Ask prescriber to submit prior authorization with AHA/ACC guideline citation | | Insured, Tier 2 placement | Request formulary exception citing Class I, Level A evidence | | Cannot swallow tablets | Ask prescriber about 503A compounding referral | | FQHC patient | Ask if site is 340B-qualified for $0 cost | | Neighbor island, limited pharmacy access | Use 90-day mail-order supply from insurer's preferred mail pharmacy |

Clinical Pharmacology and Dosing Relevant to Cost Decisions

Amlodipine besylate is available in 2.5 mg, 5 mg, and 10 mg tablets. The FDA-approved label specifies a starting dose of 5 mg once daily for hypertension in most adults, with titration to 10 mg once daily if blood pressure remains above goal after seven to fourteen days [1]. Elderly patients and those with hepatic impairment may start at 2.5 mg. The 2.5 mg tablet is less widely stocked at Hawaiian pharmacies; patients prescribed that dose may pay slightly more per milligram or need to request it specifically.

Amlodipine's long half-life (30 to 50 hours) means a missed dose is generally less consequential than with shorter-acting antihypertensives, which supports real-world adherence. The ALLHAT trial (N=33,357) found that the amlodipine arm had significantly lower rates of combined fatal coronary heart disease and non-fatal myocardial infarction compared with other antihypertensive classes in certain subgroups, reinforcing long-term value relative to cost [10]. ALLHAT remains the largest antihypertensive outcomes trial ever conducted in the United States.

Common adverse effects include peripheral edema (dose-dependent, occurring in roughly 10.8% of patients at 10 mg per day in controlled trials) and flushing [1]. These effects are pharmacodynamic, not allergic, and do not require switching drug class in most cases. Dose reduction from 10 mg to 5 mg frequently resolves edema while preserving most of the blood-pressure-lowering effect. Prescribers and pharmacists in Hawaii should counsel patients on this option before abandoning a low-cost, well-tolerated generic.

Drug interactions are clinically relevant to cost because an unrecognized interaction leading to adverse effects or hospitalizations is far more expensive than the drug itself. Cyclosporine and tacrolimus concentrations increase when co-administered with amlodipine; simvastatin dose should be capped at 20 mg daily when combined with amlodipine 10 mg daily, per the FDA drug safety communication from 2011 [11]. CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) may increase amlodipine plasma levels and warrant blood pressure monitoring.

Cost Benchmarks Across Hawaii Counties

Pharmacy density and price vary meaningfully by county. Honolulu County (Oahu) has the highest pharmacy density, with competitive pricing across Longs, Walgreens, Walmart, Costco, and numerous independent pharmacies. Hawaii County (Big Island) has significantly fewer retail pharmacies per capita, particularly in Hilo and Kona districts. Maui County and Kauai County each have fewer than ten retail pharmacy locations per 100,000 residents.

The Health Resources and Services Administration (HRSA) Uniform Data System reports that Hawaii had 22 HRSA-funded health center sites as of the most recent reporting year [8]. Patients in rural Hawaii County and Molokai, where pharmacy access is most limited, should inquire whether their community health center participates in 340B drug pricing. A 340B-eligible site can supply generic amlodipine at or near cost to qualifying patients, which may be below the already-low $8 retail cash price.

For neighbor island patients using telehealth, 90-day mail-order prescriptions remain the most practical supply strategy. Most major Part D plans and commercial insurers offer 90-day supplies at two times (rather than three times) the 30-day copay, reducing per-month cost by roughly 33%. A patient paying $8 per month cash could reduce their effective cost to approximately $5 per month with a 90-day mail-order fill.

What the Evidence Says About Long-Term Value

Hypertension affects approximately 47% of U.S. adults, and the CDC estimates that only about 24% of hypertensive adults have their blood pressure controlled to <140/90 mmHg [12]. Uncontrolled hypertension is the leading modifiable risk factor for stroke and a major driver of heart failure and chronic kidney disease. The direct medical cost of hypertension-related cardiovascular events far exceeds any pharmacy spend on amlodipine.

In ASCOT-BPLA, the amlodipine-based arm also showed a 36% relative risk reduction in new-onset diabetes compared with the atenolol-based arm (P<0.0001), a secondary finding with long-term cost implications beyond blood pressure alone [3]. The ACCOMPLISH trial (N=11,506) showed that the combination of amlodipine plus benazepril reduced the primary composite cardiovascular outcome by 19.6% compared with benazepril plus hydrochlorothiazide (P<0.001) [13]. Both trials support amlodipine as a high-value choice not only by acquisition cost but by downstream event prevention.

At $8 per month, a full year of generic amlodipine therapy in Hawaii costs $96. A single emergency department visit for a hypertensive crisis averages more than $1 to 500 in Hawaii, where healthcare costs rank among the highest in the United States. The return on investment for consistent, low-cost antihypertensive therapy is direct and measurable.